Brief: Aclaris Therapeutics Sees Cash, Cash Equivalents And Marketable Securities As Of Sep. 30 Sufficient To Fund Operations Through End Of 2025
Nov 6 (Reuters) - Aclaris Therapeutics Inc ACRS.O :
* ACLARIS THERAPEUTICS - SEES ITS CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES AS OF SEPT 30, SUFFICIENT TO FUND ITS
OPERATIONS THROUGH END OF 2025
Source text for Eikon: ID:nGNX7MH4BX
Further company coverage: ACRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Aclaris Therapeutics Q3 revenue beats analyst estimates
Brief: Aclaris Therapeutics Q3 Net Income USD -18.51 Million Vs. IBES Estimate USD -23.7 Million
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aclaris Therapeutics Q2 revenue beats analyst estimates